THELIUM THERAPEUTICS INC.

New York, NY · Founded 2019 · Biotech · Defunct

Small molecule inhibitor (Divertin) that blocks MLCK1-IgCAM3 interaction to restore intestinal barrier function

Claim this profile

Follows are private to you and power your alerts

Updated · theliumtx.com

Sector
Biotech
Headquarters
New York, NY
Founded
2019
Latest Form D
$3.1M, May 2022
Total capital
$5.1M
Federal grants
$2M
4 awards · 2019–2022
Rank in peer group#292 of 326
Private capital raised
$3.1M
1 Form D · last May 2022
54 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

2019202020212022FEDERAL ↑EQUITY ↓Cumulative $5.1M$224K$224K$795K$795K1st Form D$3.1M
2019202020212022FEDERAL ↑EQUITY ↓Cumulative $5.1M$224K$224K$795K$795K1st Form D$3.1M

Latest events

  • Federal grantHealth and Human S · Phase II · A Novel Approach to Restore Epithelial Barrier Homeostasis to Treat Inflammatory Bowel Disease$795K
  • Federal grantHealth and Human S · Phase II · A Novel Approach to Restore Epithelial Barrier Homeostasis to Treat Inflammatory Bowel Disease$795K
  • Private capital raisedForm D · SEC · 1st filing$3.1M
  • Federal grantHealth and Human S · Phase I · A Novel Approach to Restore Epithelial Barrier Homeostasis to Treat Inflammatory Bowel Disease$224K
  • Federal grantHealth and Human S · Phase I · A Novel Approach to Restore Epithelial Barrier Homeostasis to Treat Inflammatory Bowel Disease$224K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

32months

from THELIUM THERAPEUTICS INC.’s first federal award to its first private round.

First federal award · Sep 2019
Health and Human S · $224K
First Form D · May 2022
$3.1M · 1st Form D
Awards before first raise
2 awards

An association in public records, not a cause or a prediction.

Standing among 326 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Miro BrajenovicExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • RASHMIVU LLCSimilar federal contract value in Biotech · null in contracts
  • SKYRAN BIOLOGICS, INC.Similar federal contract value in Biotech · null in contracts
  • IMAGO PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
  • Nautilus BiotechnologySimilar federal contract value in Biotech · null in contracts
  • Ef Therapeutics LLCSimilar federal contract value in Biotech · null in contracts
  • Aincobio LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .